PDF icon Download PDF
Am J Perinatol 2024; 41(S 01): e2124-e2128
DOI: 10.1055/a-2099-8758
Original Article

Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia

Arianna S. Portmann-Baracco 
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Rodrigo G. Alcorta-Proaño
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Claudia Nuñez-Mochizaki
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Camille M. Webb
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
2   Department of Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, Texas
,
Juan Trelles
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Carlos Caparo
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Mauricio F. La Rosa
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
2   Department of Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, Texas
› Author Affiliations
Funding None.
› Further Information
Also available ateRefHebammen
   Permissions and Reprints
Preview

Abstract

Objective Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery.

Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G + , IgM + , or both IgG+ and IgM + . Bivariate and multivariable analyses were performed.

Results We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98–36.09; p <  0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65–18.02; p < 0.05).

Conclusion We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.

Key Points

  • Pregnant people with acute COVID-19 are at an increased risk of developing preeclampsia.

  • Seroconversion during pregnancy was not associated with an increased risk of preeclampsia.

  • Further study regarding the timing of infection and its association with preeclampsia is necessary.

Keywords

COVID-19 - SARS-CoV-2 - preeclampsia - pregnancy

Note

Poster presented at the SMFM's 42nd Annual Pregnancy Meeting, Society of Maternal Fetal Medicine, Virtual meeting, January 31–February 5, 2022.




Publication History

Received: 11 April 2022

Accepted: 22 May 2023

Accepted Manuscript online:
25 May 2023

Article published online:
26 June 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA